Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in
different ways and stop plasma cells from growing. Drugs used in chemotherapy, such as
cyclophosphamide and dexamethasone, work in different ways to stop the growth of plasma
cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide
together with cyclophosphamide and dexamethasone may be an effective treatment for primary
systemic amyloidosis.
PURPOSE: This phase II trial is studying how well giving lenalidomide together with
cyclophosphamide and dexamethasone works in treating patients with primary systemic
amyloidosis.